Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: OTCMKTS:MBLTY
- CUSIP: N/A
- Web: www.mesoblast.com/
- 50 Day Moving Avg: $12.26
- 200 Day Moving Avg: $13.71
- 52 Week Range: $10.27 - $19.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.07
- P/E Growth: 0.00
- Net Margins: -1,085.90%
- Return on Equity: -7.47%
- Return on Assets: -5.86%
- Average Volume: 1,111 shs.
Frequently Asked Questions for Mesoblast limited (OTCMKTS:MBLTY)
What is Mesoblast limited's stock symbol?
Mesoblast limited trades on the OTCMKTS under the ticker symbol "MBLTY."
Where is Mesoblast limited's stock going? Where will Mesoblast limited's stock price be in 2017?
1 brokerages have issued twelve-month price objectives for Mesoblast limited's stock. Their forecasts range from $14.00 to $14.00. On average, they expect Mesoblast limited's stock price to reach $14.00 in the next year. View Analyst Ratings for Mesoblast limited.
Who are some of Mesoblast limited's key competitors?
Some companies that are related to Mesoblast limited include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Alnylam Pharmaceuticals (ALNY), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), ACADIA Pharmaceuticals (ACAD), WuXi PharmaTech (Cayman) (WX), Sage Therapeutics (SAGE) and Portola Pharmaceuticals (PTLA).
Who are Mesoblast limited's key executives?
Mesoblast limited's management team includes the folowing people:
- Silviu Itescu, Chief Executive Officer, Executive Director
- William A. Burns, Vice Chairman of the Board
- Paul Hodgkinson, Group Chief Financial Officer
- Peter Howard, General Counsel, Corporate Executive
- Charlie Harrison, Company Secretary
- Brian Jamieson, Independent Non-Executive Chairman of the Board
- Donal Paul O'Dwyer, Non-Executive Independent Director
- Eric A. Rose M.D., Non-Executive Independent Director
- Michael R. Spooner, Non-Executive Independent Director
- Ben-Zion Weiner Ph.D., Non-Executive Independent Director
How do I buy Mesoblast limited stock?
Shares of Mesoblast limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mesoblast limited's stock price today?
MarketBeat Community Rating for Mesoblast limited (OTCMKTS MBLTY)MarketBeat's community ratings are surveys of what our community members think about Mesoblast limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Mesoblast limited stock can currently be purchased for approximately $12.33.
Consensus Ratings for Mesoblast limited (OTCMKTS:MBLTY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$14.00|
Analysts' Ratings History for Mesoblast limited (OTCMKTS:MBLTY)
(Data available from 8/16/2015 forward)
|2/27/2017||Maxim Group||Set Price Target||Buy||$14.00|
|6/15/2016||Credit Suisse Group||Downgrade||Hold|
|6/15/2016||J P Morgan Chase & Co||Reiterated Rating||Hold|
Earnings History for Mesoblast limited (OTCMKTS:MBLTY)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Mesoblast limited (OTCMKTS:MBLTY)
Current Year EPS Consensus Estimate: $-1.43 EPS
Next Year EPS Consensus Estimate: $-1.36 EPS
Dividend History for Mesoblast limited (OTCMKTS:MBLTY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Mesoblast limited (OTCMKTS:MBLTY)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Mesoblast limited (OTCMKTS:MBLTY)
Latest Headlines for Mesoblast limited (OTCMKTS:MBLTY)
Mesoblast limited (MBLTY) Chart for Wednesday, August, 16, 2017